Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmin, commonly known as GRP94 or gp96, is a 94 kDa molecular chaperone residing in the lumen of the endoplasmic reticulum (ER). As the ER-resident paralog of the heat shock protein 90 (HSP90) family, it plays a critical role in the folding, maturation, and trafficking of a specific subset of secretory and membrane-bound proteins, including Toll-like receptors (TLRs), integrins, and growth factors like IGF-II. GRP94 is essential for maintaining ER proteostasis and is a key regulator of both innate and adaptive immune responses through its role in antigen cross-presentation and immune receptor biogenesis. In disease states, GRP94 is frequently upregulated in response to ER stress, particularly within the tumor microenvironment, where it promotes cancer cell survival, proliferation, and metastasis by stabilizing oncogenic client proteins such as HER2 and LRP6. Consequently, GRP94 has emerged as a significant therapeutic target in oncology, with strategies including the development of isoform-selective small molecule inhibitors, monoclonal antibodies, and tumor-derived chaperone-peptide vaccines like vitespen. Selective inhibition of GRP94 offers a potential advantage over pan-HSP90 inhibitors by reducing systemic toxicity while effectively disrupting disease-dependent signaling pathways. Beyond cancer, GRP94 is also implicated in the pathogenesis of glaucoma and various viral infections, where it facilitates the folding of viral glycoproteins necessary for entry and replication.
GRP94 inhibitors typically act by binding to the unique ATP-binding pocket in the N-terminal domain, thereby preventing the conformational changes required for its chaperone activity and leading to the ubiquitin-mediated degradation of its client proteins.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endoplasmin (GRP94) (GRP94).